BioCryst Pharmaceuticals Future Growth
Future criteria checks 4/6
BioCryst Pharmaceuticals is forecast to grow earnings and revenue by 70.3% and 15.5% per annum respectively while EPS is expected to grow by 70.1% per annum.
Key information
70.3%
Earnings growth rate
70.1%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 15.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 06 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 601 | 46 | 191 | N/A | 7 |
| 12/31/2025 | 515 | -41 | 82 | -8 | 9 |
| 12/31/2024 | 433 | -79 | 4 | -50 | 8 |
| 6/30/2024 | 382 | -146 | -86 | -84 | N/A |
| 3/31/2024 | 355 | -209 | -104 | -101 | N/A |
| 12/31/2023 | 331 | -227 | -97 | -95 | N/A |
| 9/30/2023 | 318 | -236 | -112 | -110 | N/A |
| 6/30/2023 | 307 | -243 | -124 | -123 | N/A |
| 3/31/2023 | 290 | -226 | -133 | -132 | N/A |
| 12/31/2022 | 271 | -247 | -163 | -162 | N/A |
| 9/30/2022 | 238 | -193 | -172 | -170 | N/A |
| 6/30/2022 | 204 | -210 | -163 | -161 | N/A |
| 3/31/2022 | 188 | -194 | -162 | -159 | N/A |
| 12/31/2021 | 157 | -184 | -145 | -142 | N/A |
| 9/30/2021 | 114 | -227 | -154 | -152 | N/A |
| 6/30/2021 | 79 | -214 | -168 | -167 | N/A |
| 3/31/2021 | 32 | -209 | -173 | -173 | N/A |
| 12/31/2020 | 18 | -183 | -136 | -135 | N/A |
| 9/30/2020 | 54 | -125 | -103 | -103 | N/A |
| 6/30/2020 | 49 | -116 | -93 | -92 | N/A |
| 3/31/2020 | 48 | -115 | -86 | -86 | N/A |
| 12/31/2019 | 49 | -109 | -90 | -90 | N/A |
| 9/30/2019 | 12 | -134 | -103 | -103 | N/A |
| 6/30/2019 | 12 | -126 | -111 | -111 | N/A |
| 3/31/2019 | 23 | -107 | -100 | -100 | N/A |
| 12/31/2018 | 21 | -101 | -93 | -93 | N/A |
| 9/30/2018 | 22 | -93 | -79 | -79 | N/A |
| 6/30/2018 | 29 | -79 | -57 | -56 | N/A |
| 3/31/2018 | 20 | -77 | N/A | -52 | N/A |
| 12/31/2017 | 25 | -66 | N/A | -41 | N/A |
| 9/30/2017 | 30 | -51 | N/A | -36 | N/A |
| 6/30/2017 | 29 | -47 | N/A | -42 | N/A |
| 3/31/2017 | 31 | -47 | N/A | -43 | N/A |
| 12/31/2016 | 26 | -55 | N/A | -53 | N/A |
| 9/30/2016 | 22 | -69 | N/A | -62 | N/A |
| 6/30/2016 | 25 | -72 | N/A | -58 | N/A |
| 3/31/2016 | 46 | -51 | N/A | -28 | N/A |
| 12/31/2015 | 48 | -43 | N/A | -13 | N/A |
| 9/30/2015 | 49 | -37 | N/A | -12 | N/A |
| 6/30/2015 | 41 | -31 | N/A | -8 | N/A |
| 3/31/2015 | 17 | -50 | N/A | -33 | N/A |
| 12/31/2014 | 14 | -45 | N/A | -39 | N/A |
| 9/30/2014 | 19 | -39 | N/A | -29 | N/A |
| 6/30/2014 | 18 | -38 | N/A | -28 | N/A |
| 3/31/2014 | 17 | -36 | N/A | -24 | N/A |
| 12/31/2013 | 17 | -30 | N/A | -27 | N/A |
| 9/30/2013 | 11 | -36 | N/A | -29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCRX * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.9%).
Earnings vs Market: BCRX * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BCRX * is expected to become profitable in the next 3 years.
Revenue vs Market: BCRX *'s revenue (15.5% per year) is forecast to grow faster than the MX market (7.1% per year).
High Growth Revenue: BCRX *'s revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCRX *'s Return on Equity is forecast to be high in 3 years time